Application of Arg-AMS compounds in the preparation of anti-PRRSV drugs
Through computer screening of small-molecule compounds targeting CD163 protein, locking and applying Arg-AMS compounds to block the interaction between PRRSV and CD163, solving the problem of poor effectiveness of existing anti-PRRSV vaccines and realizing the use of pig blue ear disease virus Effectively inhibit and prevent.
Patent Information
- Application Number
- CN202311509079.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-11-13
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2043-11-13
AI Technical Summary
The existing anti-PRRSV vaccine is not effective, cannot effectively prevent virus transmission and pathogenicity of mutant strains, and lacks antiviral drugs that target host proteins.
Through computer virtual screening of small-molecular compounds targeting CD163 protein, locking down Arg-AMS compounds, blocking the interaction between PRRSV and CD163, inhibiting viral invasion and replication, and developing Arg-AMS compounds with antiviral activity.
Arg-AMS compounds significantly inhibit HP-PRRSV infection and replication, are effective for different variant strains, providing a new direction for the development of antiviral drugs, and can prevent and treat pig blue ear disease.
Smart Images

Figure CN117503791B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and more specifically, relates to the application of Arg-AMS compounds in the preparation of anti-PRRSV drugs. Background Art
[0002] my country is the largest pig farming and pork consumption country, with both farming and consumption accounting for more than half of the world's total, and pork accounting for 60% of my country's meat consumption. Disease is an important factor affecting the healthy development of the pig industry. Porcine reproductive and respiratory syndrome (PRRS), commonly known as blue ear disease, first appeared in the United States in 1987 and was subsequently reported in Europe. At present, PRRS is one of the infectious diseases that pose the greatest threat to the healthy development of the global pig industry. PRRSV mainly causes reproductive disorders in sows, respiratory symptoms in pigs of different ages, especially piglets, and secondary infections such as Haemophilus parasuis and Streptococcus infections, causing huge economic losses to the global pig industry. At present, the pathogenic mechanism of the virus and the mechanism of inducing host immune response are still unclear.
[0003] The biggest difference between PRRSV and other viruses is that it mainly infects immune cells - porcine alveolar macrophages, destroying the immune system, similar to HIV. The virus has the following characteristics: ① immunosuppression, interfering with other vaccine immunity; ② highly variable, extremely easy to mutate and recombine, producing more pathogenic strains; ③ no / low neutralizing antibodies, the main antigenic epitope GP5 protein that baits the production of neutralizing antibodies is not fully exposed on the surface of the virus particles; ④ inflammatory storm, excessive induction of cytokine expression; ⑤ antibody-dependent enhancement (ADE), low\non-neutralizing antibodies promote virus invasion; ⑥ persistent infection, long viremia, intermittent detoxification; ⑦ secondary infection, secondary infection with Haemophilus parasuis, Streptococcus, etc.
[0004] Based on the above characteristics of PRRSV, combined with years of practical experience, the commercial vaccines currently developed, including attenuated and inactivated vaccines, are not ideal and cannot prevent the occurrence and spread of the disease. In addition, these vaccines have the following problems: slow production of neutralizing antibodies, poor cross-protection against heterologous strains, long vaccine virus viremia, and recombinant viruses with stronger pathogenicity produced by recombination with field strains. Therefore, the development of more and more efficient antiviral drugs is an important direction for the prevention and control of PRRS.
[0005] Based on the principle of virus-host interaction, the development of antiviral drugs targets viral proteins and host proteins. Since PRRSV is an RNA virus and is very easy to mutate, antiviral drugs targeting viral proteins may be ineffective against mutants due to viral mutations. Host proteins will not change due to viral mutations. Therefore, targeting host proteins to block viral replication and then developing antiviral drugs can prevent and treat different mutants of PRRSV. "Respond to changes with constancy." No matter how PRRSV mutates, antiviral drugs targeting host proteins are effective. However, there is currently a severe lack of antiviral drugs that can target host proteins. Summary of the invention
[0006] The technical problem to be solved by the present invention is to overcome the defects and shortcomings of existing blue ear disease prevention and treatment and antiviral drugs targeting host proteins, and provide the use of Arg-AMS compounds in the preparation of anti-PRRSV drugs.
[0007] The invention provides a new use of an Arg-AMS compound in preparing a drug for resisting PRRSV virus or preventing and treating porcine blue ear disease.
[0008] Another object of the present invention is to provide a drug for resisting PRRSV virus or treating porcine blue ear disease.
[0009] The above-mentioned purpose of the present invention is achieved through the following technical solutions:
[0010] The present invention utilizes computer virtual screening of small molecule compounds targeting CD163 protein, blocks the interaction between PRRSV and CD163, and finally locks Arg-AMS compounds, and finds for the first time that Arg-AMS compounds have antiviral activity, and have significant antiviral effects on porcine blue ear disease virus. PRRSV is treated with Arg-AMS compounds of different concentrations, and then samples are collected and tested by western-blot, immunofluorescence IFA, plaque assay, etc., to detect the expression of PRRSV-N protein and viral titer, and different means are used to prove that Arg-AMS can significantly inhibit HP-PRRSV infection and replication, has a good antiviral effect, and is effective for different variants of PRRSV, especially for highly pathogenic strains HP-PRRSV. It still has a significant antiviral effect. Therefore, the present invention shows that Arg-AMS compounds are expected to become new bioactive molecules for the prevention and treatment of porcine blue ear disease, and have a good application prospect in the prevention and treatment of porcine blue ear disease.
[0011] Arg-AMS compound is an arginyl tRNA synthetase inhibitor that can bind tightly to the A domain of non-ribosomal peptide synthetases (NRPSs). Its molecular weight is 502.51 and its molecular formula is: C 16 H26 N 10 O7S, structural formula:
[0012]
[0013] Therefore, the present invention provides the following uses of Arg-AMS compounds:
[0014] Application in the preparation of drugs against PRRSV virus.
[0015] Furthermore, the drug prevents viral infection by targeting the host protein CD163 of the PRRSV virus and blocking the interaction therewith.
[0016] Preferably, the PRRSV virus is highly pathogenic porcine blue ear disease virus HP-PRRSV.
[0017] Furthermore, the drug is antiviral by blocking the expression and replication of the virus.
[0018] Application in the preparation of medicines for treating blue ear disease in pigs.
[0019] Furthermore, the porcine reproductive and respiratory syndrome (PRRS) is the PRRSV caused by the highly pathogenic porcine reproductive and respiratory syndrome virus (HP-PRRSV) or the PRRSV caused by a virus variant.
[0020] Preferably, the virus variant is PRRSV Ch-1a strain, WuH3 strain or SD16 strain.
[0021] In addition, the present invention also provides a drug for resisting PRRSV virus or treating blue ear disease in pigs, wherein the drug contains the Arg-AMS compound.
[0022] Preferably, the concentration of the Arg-AMS compound in the drug is 1 to 50 μM.
[0023] More preferably, the concentration of the Arg-AMS compound in the drug is 2-10 μM.
[0024] Further preferably, the dosage form of the drug can be prepared into different desired dosage forms, such as injection preparations or oral preparations, such as capsules, tablets, etc.
[0025] The present invention has the following beneficial effects:
[0026] The present invention proves for the first time that Arg-AMS has antiviral activity and has strong resistance to porcine blue ear virus, especially it still has significant antiviral effect on highly pathogenic strain HP-PRRSV. Studies have shown that Arg-AMS can target host protein CD163 (an essential receptor for PRRSV invasion), block the interaction between PRRSV and CD163, and inhibit viral invasion, so it will not be ineffective due to viral mutations, that is, it has antiviral activity against different mutants. At the same time, due to the small molecular weight of Arg-AMS, it is very easy to pass through the cell membrane into the cell and exert an antiviral effect, so it does not need a carrier to be delivered into the cell, which lays the foundation for the development of new drugs against porcine blue ear disease. The present invention provides a new use of Arg-AMS compounds, provides a basis for the development of PRRSV antiviral drugs, and provides more methods and means for the prevention and treatment of porcine blue ear disease. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 This is a toxicity test of Arg-AMS compounds on Marc-145 cells.
[0028] Figure 2 After PRRSV was treated with Arg-AMS at different concentrations, the expression level of PRRSV-N protein was detected by western-blot.
[0029] Figure 3 After PRRSV was treated with different concentrations of Arg-AMS, the expression level of PRRSV-N protein was detected by immunofluorescence analysis (IFA).
[0030] Figure 4 After PRRSV was treated with different concentrations of Arg-AMS, the cell supernatant was collected and the virus titer was detected by plaque assay. DETAILED DESCRIPTION
[0031] The present invention is further described below in conjunction with the accompanying drawings and specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.
[0032] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.
[0033] Statistical analysis of the following examples of the present invention: All experiments were repeated at least 3 times independently, and the results were expressed as mean values and standard errors, and analyzed using one-way analysis of variance and T test. All statistical analyses used P<0.05 as the test standard for significant statistical differences, and the analysis software was SPSS16.0 and GraphPad Prism 5.
[0034] The cells and PRRSV strains used in the following examples were all sourced and stored in the laboratory of the research group of the present invention. Arg-AMS was provided by MedChemExpress (MCE), CAS No.: 301351-95-1.
[0035] Example 1 Screening of small molecule compounds targeting CD163
[0036] Since CD163 is an essential receptor for PRRSV invasion, the present invention first uses computer virtual screening of small molecule compounds targeting CD163 protein to block the interaction between PRRSV and CD163 and inhibit virus invasion. The software used for virtual screening is Maestro 11.4, 3D drawing software is PyMol.
[0037] 1. Protein preparation
[0038] The crystal structure of Sus scrofa CD163 was downloaded from the RCSB PDB database (PDB ID: 5HRJ), and the protein was hydrogenated using the Protein Preparation Wizard module. Energy optimization was then performed (OPLS2005 force field, RMSD ), use the Receptor Grid Generation module to create a grid file for the processed protein, and generate a grid file with CYS486 / CYS515 / CYS520 / CYS576 as the center. The box size is set to
[0039] 2. Compound preparation
[0040] The 2D format of the MCE Bioactive Compound Library Plus (containing 16.7K compounds) was converted to The software LigPrep Module performs hydrogenation, energy optimization and other processing, and outputs 3D structures for virtual screening.
[0041] 3. Molecular docking
[0042] The Virtual Screening Workflow module was used for virtual screening, the prepared compounds were imported, and the Glide module was used for molecular docking, that is, the receptor and ligand molecules were docked with each other through geometric matching and energy matching. First, the high-throughput screening (HTVS) mode in the Glide module was used to screen the small molecule compounds of the MCE Bioactive Compound Library Plus, and the small molecule compounds with the top 15% of the scores were selected for the second round of screening using the standard (SP) mode; then the top 15% of the scores were selected for the third round of screening using the high-precision (XP) mode to obtain the ranking of small molecule compounds. Finally, the binding force between the target and the compound, the compound structure, etc. were manually reviewed, and the top 200 compounds in the MCE Bioactive Compound Library Plus were selected for output and delivered as the final result. The binding mode of the top 5 compounds in the MCEBioactive Compound Library Plus with the Sus scrofa CD163 protein was selected for 2D and 3D mapping.
[0043] 4. Analysis of screening results
[0044] The higher the absolute value of the molecular docking score (docking_score), the stronger the binding force between the compound and the protein. According to the score ranking of the intermolecular interaction force between the small molecule compound and CD163, the Arg-AMS compound was finally locked.
[0045] Example 2 Arg-AMS cytotoxicity experiment
[0046] 1. Materials
[0047] Arg-AMS powder (purchased from MedChemExpress (MCE)). AlamarBlue (purchased from Invitrogen) is used as a metabolic indicator for living cells. It produces measurable fluorescent metabolites under mitochondrial enzymatic reduction reactions, and cell activity can be monitored by measuring its fluorescence intensity.
[0048] 2. Test methods
[0049] Marc-145 cells (or PAMs cells) were cultured with DMEM culture medium containing 10% fetal bovine serum until 60-70%, the culture medium was discarded, and nutrient solutions containing Arg-AMS diluted in multiples (DMSO dilution concentrations were: 0.1, 0.2, 0.5, 1, 2, 5, 10, 20, 50 μM) were added for 36 hours, a DMSO control group was set, and then 10% (v / v) AlamarBlue was added and cultured for 3 hours; a multifunctional microplate reader was used to read the fluorescence values of 540nm excitation light and 590nm emission light, and an Arg-AMS cytotoxicity graph was drawn. The cell activity of the DMSO control group was taken as 100%, and the fluorescence value of the cells treated with the multiple dilutions of Arg-AMS was divided by the fluorescence value of the PBS control group, which was the relative cell activity of Arg-AMS at different concentrations.
[0050] 3. Results
[0051] The cytotoxicity results of Arg-AMS are as follows Figure 1 As shown, even when the concentration of Arg-AMS reached 50 μM, the cell activity was 100% compared with the DMSO control group, and it was non-toxic to Marc-145 cells, indicating that Arg-AMS had minimal toxicity to cells.
[0052] Example 3 Arg-AMS antiviral test
[0053] 1. Western blot detection
[0054] Marc-145 cells were cultured in a 6-well plate in DMEM culture medium containing 10% fetal bovine serum until the cell confluence was 70%, the culture medium was discarded, the cells were washed three times with PBS, HP-PRRSV was inoculated with an infection multiplicity MOI = 1, and different concentrations of Arg-AMS compounds were added at the same time. A control group without Arg-AMS was set up, and then the cells were cultured in a 37°C, 5% CO2 incubator. After 36 hours, they were washed three times with PBS, digested with 0.25% trypsin, the cells were lysed, the protein concentration was measured, and the expression level of PRRSV-N protein was detected by Western-Blot.
[0055] The results are as follows Figure 2 As shown, Arg-AMS significantly inhibited the expression of PRRSV-N protein, and as the concentration of Arg-AMS increased, the inhibitory effect became more obvious and dose-dependent. The above experimental results show that Arg-AMS can inhibit the expression of PRRSV-N protein.
[0056] 2. Immunofluorescence (IFA) detection
[0057] Marc-145 cells were cultured in a 6-well plate in DMEM culture medium containing 10% fetal bovine serum until the cell confluence was 70%, the culture medium was discarded, the cells were washed three times with PBS, HP-PRRSV was inoculated with an infection multiplicity MOI = 1, and different concentrations of Arg-AMS compounds were added at the same time. A control group without Arg-AMS was set up, and then cultured in a 37°C, 5% CO2 incubator. After 36 hours, the cells were washed three times with PBS, and the cells were fixed with 4% paraformaldehyde. Immunofluorescence (IFA) was used to detect the expression level of PRRSV-N protein.
[0058] The results are as follows Figure 3 As shown, Arg-AMS significantly inhibited the expression of PRRSV-N protein, and as the concentration of Arg-AMS increased, the inhibitory effect became more obvious and dose-dependent. The above experimental results show that Arg-AMS has significant antiviral activity against PRRSV.
[0059] 3. Plaque assay (PFU) detection
[0060] Marc-145 cells were cultured in a 6-well plate in DMEM culture medium containing 10% fetal bovine serum until the cell confluence reached 70%. The culture medium was discarded, the cells were washed three times with PBS, and HP-PRRSV was inoculated at a multiplicity of infection MOI = 1. At the same time, different concentrations of Arg-AMS compounds were added, and a control group without Arg-AMS was set up. The cells were then cultured in a 37°C, 5% CO2 incubator. After 36 hours, the cell supernatant was collected and the virus titer was detected by plaque assay.
[0061] The results are as follows Figure 4 As shown, Arg-AMS significantly inhibited PRRSV replication (the number of plaques was significantly reduced), and as the concentration of Arg-AMS increased, the inhibitory effect became more obvious and dose-dependent. The above experimental results show that Arg-AMS has significant antiviral activity against PRRSV.
[0062] In addition, the present invention also tested the antiviral activity of Arg-AMS against different variants of PRRSV Ch-1a, WuH3 and SD16 according to the above method. The results showed that Arg-AMS had a significant inhibitory effect on different strains of PRRSV.
[0063] In summary, the present invention has proved for the first time that Arg-AMS has antiviral activity and has strong resistance to porcine blue ear virus, especially has significant antiviral effect on highly pathogenic strain HP-PRRSV; Arg-AMS can target host protein CD163, block the interaction between PRRSV and CD163, and inhibit virus invasion, so it will not be invalid due to virus mutation, that is, it has antiviral activity against different mutants. At the same time, due to the small molecular weight of Arg-AMS, it is very easy to pass through the cell membrane into the cell and exert an antiviral effect, so there is no need for carrier delivery into the cell, which lays the foundation for the development of new drugs against porcine blue ear disease. The present invention provides a new use of Arg-AMS compounds, provides a basis for the development of PRRSV antiviral drugs, and provides more methods and means for the prevention and treatment of porcine blue ear disease.
[0064] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. Use of an Arg-AMS compound in the preparation of a drug for resisting PRRSV virus, wherein the structural formula of the Arg-AMS compound is: .
2. The use according to claim 1, It is characterized in that The PRRSV virus is highly pathogenic porcine blue ear disease virus HP-PRRSV.
3. Use of an Arg-AMS compound in the preparation of a drug for treating porcine blue ear disease, wherein the structural formula of the Arg-AMS compound is: .
4. The use according to claim 3, It is characterized in that The porcine blue ear disease is the blue ear disease caused by the highly pathogenic porcine blue ear disease virus HP-PRRSV or the blue ear disease caused by a variant strain of PRRSV.
5. The use according to claim 4, It is characterized in that The virus variant strain is PRRSV Ch-1a strain, WuH3 strain or SD16 strain.
Citation Information
Patent Citations
Application of tea polyphenols in prevention and treatment of porcine reproductive and respiratory syndrome
CN109010331A
Application of MARCH5 in identifying susceptibility of pigs to porcine reproductive and respiratory syndrome virus and preparing medicine
CN115678985A
Application of hypericum japonicum thumb extract in the preparation of a drgu against the blue-ear disease
US20230076197A1
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-TRNA synthetases
WO2011139986A2
